Ex vivo

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Giovedì, Maggio 2, 2024
Oncology, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Kélonia, Multiple myeloma, Date, Ex vivo, Cell, Protein, Patient, Gene, Society, PEGS, Medicine, Therapy, BCMA, Pharmaceutical industry

“Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.

Key Points: 
  • “Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.
  • “Combining this platform with our proprietary, fully-human, and highly active BCMA CAR candidate creates a medicine with the potential to transform the treatment of multiple myeloma.
  • With KLN-1010 poised to be the first in vivo CAR-T cell therapy for multiple myeloma, we aim to provide a potentially life-changing solution for patients that need it most.
  • ET
    PEGS Boston Summit – Therapeutics: In Vivo Cell and Gene Engineering
    Date and Time: Friday, May 17, 2024 at 9:30 – 10:00 a.m.

Global Gene Therapy Market 2022-2027: High Incidence of Cancer & Other Targeted Diseases to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Agosto 10, 2022
Health, Genetics, Retrovirus, Incidence, Research, Ex vivo, Duchenne muscular dystrophy, CAGR, Lists of diseases, Region, USD, Growth, Vaccine, Cancer

Factors such as rising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth.

Key Points: 
  • Factors such as rising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth.
  • However, factors like high cost of gene therapy is restraining the growth of this market.
  • The cancer segment accounted for the highest growth rate in the gene therapy market, by indication, during the forecast period
    In 2021, cancer segment accounted for the highest growth rate.
  • This report provides a detailed picture of the global gene therapy market.

In-Vivo Micro Computed Tomography to Account for over 3/4th of the global Market throughout the Analysis Period, States Future Market Insights

Retrieved on: 
Mercoledì, Giugno 1, 2022
Ex vivo, Greater New York, Dentistry, List of life sciences, Growth, Antibody, ESOMAR, Industry, Greater New York Chamber Of Commerce, Plant, Product type, CAGR, Commerce, Medical device, Food, Geology

NEWARK, Del., June 1, 2022 /PRNewswire/ -- The Micro Computed Tomography Market revenues were estimated at US$ 190.3 Mn in 2021 and is anticipated to grow at a CAGR of 11.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 608.7 Mn. In-Vivo Micro Computed Tomography to Register an Absolute Dollar Opportunity of US$ 346 Mn.

Key Points: 
  • Future Market Insights, in its new offering, presents an unbiased analysis of the Micro Computed Tomography Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
  • Home Rehabilitation Services Market - The global home rehabilitation services market totaled US$ 84.1 Bn in 2021.
  • Disposable Blood Pressure Cuffs Market - The disposable blood pressure cuffs market is projected to acquire a CAGR of 12.3% from 2022 to 2032.
  • Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.

In-Vivo Micro Computed Tomography to Account for over 3/4th of the global Market throughout the Analysis Period, States Future Market Insights

Retrieved on: 
Mercoledì, Giugno 1, 2022
Ex vivo, Greater New York, Dentistry, List of life sciences, Growth, Antibody, ESOMAR, Industry, Greater New York Chamber Of Commerce, Plant, Product type, CAGR, Commerce, Medical device, Food, Geology

NEWARK, Del., June 1, 2022 /PRNewswire/ -- The Micro Computed Tomography Market revenues were estimated at US$ 190.3 Mn in 2021 and is anticipated to grow at a CAGR of 11.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 608.7 Mn. In-Vivo Micro Computed Tomography to Register an Absolute Dollar Opportunity of US$ 346 Mn.

Key Points: 
  • Future Market Insights, in its new offering, presents an unbiased analysis of the Micro Computed Tomography Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
  • Home Rehabilitation Services Market - The global home rehabilitation services market totaled US$ 84.1 Bn in 2021.
  • Disposable Blood Pressure Cuffs Market - The disposable blood pressure cuffs market is projected to acquire a CAGR of 12.3% from 2022 to 2032.
  • Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting

Retrieved on: 
Martedì, Marzo 8, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Publication, NASDAQ, MT1-MMP, CD137, Bicycle, Private Securities Litigation Reform Act, Drug development, Company, U.S. Securities and Exchange Commission, Therapy, Webcast, Cancer research, Annual report, Conference, Investor, Phase, Thromboxane A2, Dana–Farber Cancer Institute, BTC, Security (finance), American Association, Review, Ex vivo, Belfer Center for Science and International Affairs, COVID-19, Drug discovery, SEC, Association, Biotechnology, Forward-looking statement, Pharmaceutical industry, Vaccine

The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m.

Key Points: 
  • The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m.
  • Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m.
  • A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Global Toxicology Services Industry Analysis 2021 to 2028 | Emergence of Advanced Technologies, Increase in Utilization of Nano-Materials, Regulatory Changes to Enhance Safety Profiles of Agents

Retrieved on: 
Lunedì, Novembre 29, 2021
Agrochemical, Ex vivo, Chronic toxicity, Government, Adoption, Medication, Geography, Environment, Safety, Pharmacology, Industry, Biochemistry, CAGR, Toxicology, ATR, Pesticide, Drug discovery, Development of the human body, LabCorp, APT, Overseas Consultants Inc., SGS, Medicine, 3D, LLC, Food, Cosmetics, Neurotoxicity, Toxicity, APAC, Pet, Fine chemical

DUBLIN, Nov. 29, 2021 /PRNewswire/ -- The "Toxicology Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 29, 2021 /PRNewswire/ -- The "Toxicology Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • According to analysis, the global toxicology services market is expected to grow at a mid single-digit CAGR from 2021 to 2028, to reach $17.04 billion by 2028.
  • Whereas, the emergence of advanced technology likes 3D-model, ex-vivo, organ-on-a chip and in-silico tool, increasing in utilization of nano-materials and regulatory changes to enhance safety profiles of agents will provide immense growth opportunities for toxicology services market in future.
  • Among the study methodologies, in-vitro toxicity services accounted for the highest revenue in 2021 and are expected grow at a mid single digit CAGR from 2021 to 2028.

Global Toxicology Services Market Forecast to 2028: A $17+ Billion Opportunity Assessment - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Novembre 26, 2021
Manufacturing, Hospitals, Health, Pharmaceutical, Chemicals, Plastics, Agrochemical, Ex vivo, Chronic toxicity, Government, Adoption, Medication, Geography, Environment, Safety, Pharmacology, Industry, Biochemistry, CAGR, Toxicology, ATR, Pesticide, Drug discovery, Development of the human body, LabCorp, APT, Overseas Consultants Inc., SGS, Medicine, 3D, LLC, Food, Cosmetics, Neurotoxicity, Toxicity, APAC, Pet, Fine chemical

According to analysis, the global toxicology services market is expected to grow at a mid single-digit CAGR from 2021 to 2028, to reach $17.04 billion by 2028.

Key Points: 
  • According to analysis, the global toxicology services market is expected to grow at a mid single-digit CAGR from 2021 to 2028, to reach $17.04 billion by 2028.
  • The market for toxicology services is segmented based on study methods, industry, end-points, and geography.
  • The In-vitro toxicology services market is further segmented in to Cellular & Biochemical assays, Ex Vivo and 3D-model and Organ-on-a-chips.
  • The toxicology services global market is competitive and all the players in this market are involved in adopting advanced technologies in toxicology studies to expand their service offerings and maintain their market shares.

ProtoKinetix Releases Third in a Series of Scientific Update Videos

Retrieved on: 
Martedì, Febbraio 26, 2019
Stem cells, Health, Biotechnology, Biology, Branches of biology, Life sciences, Biotechnology, Induced stem cells, Cell biology, Cloning, Developmental biology, Stem cell, Ex vivo

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently being tested.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently being tested.
  • The third video is an update on the testing in the University of British Columbia.
  • The goal will be to determine whether AAGP enhances the ex vivo survival and maintenance of these valuable stem cells.
  • The study is being conducted under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics.